OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Moroney on the Evaluation of COM701 Plus BMS-986207 and Nivolumab in Ovarian Cancer

December 9th 2022

John Moroney, MD, discusses the evaluation of COM701 plus BMS-986207 and nivolumab in platinum-resistant ovarian cancer.

Dr. Yeku on the Evaluation of COM701 Plus Nivolumab in Platinum-Resistant Ovarian Cancer

December 9th 2022

Oladapo Yeku, MD, PhD, FACP, discusses the evaluation of COM701 with nivolumab in patients with platinum-resistant epithelial ovarian cancer.

Dr. Jacot on Ribociclib Dose Reduction in HR+/HER2– Advanced Breast Cancer

December 9th 2022

William Jacot, MD, PhD, discusses updated efficacy and safety results from the phase 2 AMALEE trial.

Dr. Hurvitz on Sequencing Therapeutic Options in HER2+ Breast Cancer

December 8th 2022

Sara A. Hurvitz, MD, discusses sequencing therapeutic options for patients with HER2-positive breast cancer.

Dr. Romancik on Maximizing CAR T-cell Therapy in NHL

December 8th 2022

Jason Romancik, MD, discusses efforts to maximize the efficacy of CAR T-cell therapy in non-Hodgkin lymphoma.

Dr. Susanibar-Adaniya on the Impact of the MAIA and GRIFFIN Trials in Multiple Myeloma Treatment

December 8th 2022

Sandra P. Susanibar-Adaniya, MD, discusses 2 key trials in multiple myeloma that improved the treatment landscape for transplant-eligible and ineligible patients.

Dr. Bardia on Elacestrant in ER+/HER2– Metastatic Breast Cancer

December 8th 2022

Aditya Bardia, MD, MPH, discusses the use of elacestrant in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer.

Dr. Hurvitz on Trastuzumab Deruxtecan in Unresectable/Metastatic HER2+ Breast Cancer

December 7th 2022

Sara A. Hurvitz, MD, discusses updated survival data with fam-trastuzumab deruxtecan-nxki in HER2-positive, unresectable/metastatic breast cancer.

Dr. Abdou on Race and Clinical Outcomes in Breast Cancer

December 7th 2022

Yara Abdou, MD, discusses racial disparities in breast cancer outcomes in patients enrolled to the phase 3 RxPONDER trial.

Dr. Krop on Trastuzumab Deruxtecan in HER2+ Metastatic Breast Cancer

December 7th 2022

Ian Krop, MD, PhD, discusses findings from the phase 3 DESTINY-Breast02 trial in patients with HER2-positive metastatic breast cancer.

Dr. Patel on Adjuvant Nivolumab Plus Ipilimumab Regimens in Stage IV Melanoma

December 6th 2022

Sapna Patel, MD, discusses the evaluation of adjuvant nivolumab plus ipilimumab in stage IV metastatic melanoma with no evidence of disease.

Dr. Patel on Choosing a Chemoimmunotherapy Treatment in NSCLC

December 6th 2022

Manish Patel, MD, DO, discusses choosing a chemoimmunotherapy regimen for patients with advanced, metastatic non–small cell lung cancer.

Dr. Rocconi on the Impact of the SORAYA Trial in FRα+ Ovarian Cancer Treatment

December 6th 2022

Rodney Rocconi, MD, discusses the impact of the phase 3 SORAYA trial in folate receptor alpha–positive ovarian cancer.

Dr. Zhu on Key Results From the TOPAZ-1 Trial in Biliary Tract Cancer

December 6th 2022

Mojun Zhu, MD, discusses key findings from the phase 3 TOPAZ-1 trial in patients with biliary tract cancer.

Dr. Kamath on the Prevalence of FGFR2 Fusions/Rearrangements in Cholangiocarcinoma

December 5th 2022

Suneel Kamath, MD, discusses the prevalence of FGFR2 fusions or rearrangements in cholangiocarcinoma.

Dr. Jonas on the Exploration of Uproleselan Plus Standard Therapies in AML

December 5th 2022

Brian Andrew Jonas, MD, PhD, discusses the exploration of uproleselan plus standard therapies in acute myeloid leukemia.

Dr. Fonkoua on Determining First-Line Treatment Strategies in HCC

December 5th 2022

Lionel Kankeu Fonkoua, MD, discusses key considerations when selecting a treatment regimen for patients with hepatocellular carcinoma.

Dr. Rhodes on Evaluating the Unmet Needs of Elderly Patients in CLL

December 2nd 2022

Joanna M. Rhodes, MD, discusses evaluating the unmet needs of elderly patients in CLL.

Dr. Schiller on JAK Inhibitors in Myelofibrosis

December 2nd 2022

Gary J. Schiller, MD, discusses the benefits and challenges associated with JAK-directed therapies in the treatment of patients with myelofibrosis.

Dr. Liu on ADCs Under Exploration in NSCLC

December 1st 2022

Stephen V. Liu, MD, discusses the expanding exploration of antibody-drug conjugates in non–small cell lung cancer.